Biotech Index Retraces Gains as Weak Trial Data and Market Fears Weigh

BioPharma Dive’s latest data‑visualization piece examines why biotech stocks have slipped recently and highlights the rapid pace of startup acquisitions this year.

The XBI index, a barometer for biotech equities, surged to nearly $170 in August, more than doubling its level a year earlier. Since that peak, the index has drifted lower as a string of disappointing clinical trial readouts, rising interest rates and uncertainty surrounding the midterm elections have dampened investor confidence.

Adding to the pressure, the pace of public company acquisitions has slowed, removing a source of momentum for the sector and contributing to the sideways trading pattern observed in recent weeks.